My lab focuses on integrating nanotechnology with biomedicine, particularly in cancer immunology/therapy and regenerative medicine. Our first research direction is developing novel synthetic nanocarriers and engineered targeted exosomes to address gene delivery issues. These exosomes can carry therapeutic mRNA and penetrate tissue/tumor barriers through specific targeting to meet therapeutic needs (Chiang, et al. Blood, 2019; Chiang, et al. Nature Communication, 2023). The second direction involves using micro/nanoscale biochips to capture and study single cancer stem cells or exosomes to explore their cellular biology under treatment (Chiang, et al. Cell Reports, 2022; Hong Li* & CL Chiang*, co-first authors, et al. Advanced Science. 2024; Hong Li* & CL Chiang*, co-first authors, et al. Advanced Science. 2025), and to achieve precise cell editing and reprogramming. With my interdisciplinary background and training in biochemistry, bioengineering, immunology, and hematology, I aim to make a substantial impact in this cutting-edge medical field. 

   Currently, our lab is working on two main projects: (i) Liquid biopsy and exosome detection: We target exosomes in patient body fluids using biochips for liquid biopsy to track molecular targets of various malignant cancers and identify new therapeutic targets. (ii) Dual-targeting system and RNA drug delivery: We use a dual-targeting system formed by monoclonal antibodies and specific peptide chains to encapsulate therapeutic RNA drugs into extracellular vesicles and deliver them specifically to diseased areas in vivo. These projects focus on two particularly aggressive cancers: highly fibrotic pancreatic cancer and small cell lung cancer. The five-year survival rates for these cancers are only 6% and 2%, respectively, and there are no effective second-line drugs available clinically. Through our research, we hope to provide new treatment options for these challenging cancers and significantly impact clinical treatment strategies and patient outcomes.